



PTO/SB/8b(06-09)

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/510,204 |
| Filing Date | February 15, 2005 |
| First Named Inventor | BLAKELY, et al. |
| Art Unit | 1612 |
| Examiner Name | PACKARD, B. |
| Attorney Docket Number | 26376U |

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-----------------------|--------------------------|---|----------------|
| | 1 | JACKSON, T.W., et al., "Correlation of Serum Ibuprofen Concentration with Clinical Signs of Toxicity in Three Canine Exposures", <u>Vet Hum Toxicol</u> , Vol. 33, No. 5, Pgs. 486-488, (1991). | |
| | 2 | TSUCHIYA, Y., et al., "Early Pathophysiological Features in Canine Renal Papillary Necrosis Induced by Nefiracetam", <u>Toxicol Pathol</u> , Vol. 33, No. 5, Pgs. 561-569, (2005). | |
| | 3 | POORTINGA, E.W., et al., "A case-control study of acute ibuprofen toxicity in dogs", <u>Prev Vet Med</u> , Vol. 35, No. 2, Pgs. 115-124, (1998). | |
| | 4 | RIMADYL, Product Description: Indications; Dosage and Administration, 2 pages. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.